ATE501252T1 - Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns - Google Patents

Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns

Info

Publication number
ATE501252T1
ATE501252T1 AT05705076T AT05705076T ATE501252T1 AT E501252 T1 ATE501252 T1 AT E501252T1 AT 05705076 T AT05705076 T AT 05705076T AT 05705076 T AT05705076 T AT 05705076T AT E501252 T1 ATE501252 T1 AT E501252T1
Authority
AT
Austria
Prior art keywords
foxm1b
tumor cell
sirna molecules
sirns
foxm1
Prior art date
Application number
AT05705076T
Other languages
English (en)
Inventor
Robert Costa
I-Ching Wang
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Application granted granted Critical
Publication of ATE501252T1 publication Critical patent/ATE501252T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05705076T 2004-06-22 2005-01-06 Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns ATE501252T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58214104P 2004-06-22 2004-06-22
PCT/US2005/000276 WO2006009575A1 (en) 2004-06-22 2005-01-06 METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA

Publications (1)

Publication Number Publication Date
ATE501252T1 true ATE501252T1 (de) 2011-03-15

Family

ID=34960668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05705076T ATE501252T1 (de) 2004-06-22 2005-01-06 Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns

Country Status (6)

Country Link
US (1) US20100098663A2 (de)
EP (2) EP2298896A1 (de)
JP (1) JP4852539B2 (de)
AT (1) ATE501252T1 (de)
DE (1) DE602005026811D1 (de)
WO (1) WO2006009575A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004100977A1 (en) * 2003-03-25 2004-11-25 The Board Of Trustees Of The University Of Illinois Inhibition of tumor cell proliferation by foxm1b inhibitors
US8029980B2 (en) * 2006-09-29 2011-10-04 The Board Of Trustees Of The University Of Illinois Identification and use of agents that modulate oncogenic transcription agent activity
JP6238319B2 (ja) * 2013-03-27 2017-11-29 国立大学法人 長崎大学 創傷または線維症の治療剤
CN105392790B (zh) 2013-08-19 2019-04-19 豪夫迈·罗氏有限公司 4H-吡啶并[1,2-a]嘧啶-4-酮化合物制备用于预防或治疗癌症的药物的用途
WO2016128343A1 (en) * 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
EP3053577A1 (de) 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Verbindungen zur Krebsbehandlung
WO2024106737A1 (ko) * 2022-11-16 2024-05-23 한양대학교 에리카산학협력단 Foxm1 돌연변이체 또는 foxm1 shrna를 포함하는 암 치료용 약학 조성물

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
CA1310924C (en) 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5089475A (en) * 1989-02-07 1992-02-18 Brigham And Women's Hospital Treatment of ventilator dependency with growth hormone
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
EP0642589A4 (de) 1992-05-11 1997-05-21 Ribozyme Pharm Inc Methode und reagenz zur inhibierung der viralen replikation.
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5902880A (en) 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
CA2207593A1 (en) 1994-12-13 1996-06-20 John Gustofson Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
AU705035B2 (en) 1995-06-07 1999-05-13 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
US5723313A (en) * 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
US6407062B1 (en) * 1995-09-27 2002-06-18 St. Jude Children's Research Hospital ARF-P19, a novel regulator of the mammalian cell cycle
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
JP2001510808A (ja) 1997-07-24 2001-08-07 イネックス ファーマシューティカルズ コーポレイション 核酸触媒の供給のためのリポソーム組成物
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
WO1999031262A2 (en) 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6613750B2 (en) * 1998-03-19 2003-09-02 Albert Einstein College Of Medicine Of Yeshiva University Method of inhibiting cell proliferation using an anti-oncogene protein
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
EP2314700A1 (de) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Zusammensetzung und Verfahren zur in vivo und in vitro Abschwächung der Genexpression mittels dobbelsträngiger RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
GB9930519D0 (en) * 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins
WO2002045717A1 (en) * 2000-12-06 2002-06-13 Tularik Inc. Lometrexol combination therapy
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
EP1532249A2 (de) * 2002-08-21 2005-05-25 The University of British Columbia Inhibitorische rns sonden gegen krebs-assozierte proteine
WO2004019761A2 (en) * 2002-08-28 2004-03-11 The Board Of Trustees Of The University Of Illinois Methods of treating age-related defects and diseases
US8090542B2 (en) * 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
WO2004100977A1 (en) * 2003-03-25 2004-11-25 The Board Of Trustees Of The University Of Illinois Inhibition of tumor cell proliferation by foxm1b inhibitors
US7625716B2 (en) * 2003-11-26 2009-12-01 Vanderbilt University Methods for assessing p19-Arf interactions in cMyc
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9507178B1 (en) 2013-08-29 2016-11-29 Charles Wesley Blackledge Electromagnetic waveguide assembly
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
EP2298896A1 (de) 2011-03-23
US20100098663A2 (en) 2010-04-22
US20090075376A1 (en) 2009-03-19
DE602005026811D1 (de) 2011-04-21
WO2006009575A1 (en) 2006-01-26
JP2008503234A (ja) 2008-02-07
EP1758999B1 (de) 2011-03-09
EP1758999A1 (de) 2007-03-07
JP4852539B2 (ja) 2012-01-11

Similar Documents

Publication Publication Date Title
ATE477337T1 (de) Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
ATE507305T1 (de) Verfahren zur nukleinsäureimmobilisierung
IL190796A (en) Composition containing nucleic acid encoded by anti-osteoclastogenic protein
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
ATE533502T1 (de) Verfahren zur modulation der il-23-aktivität; relevante reagenzien
ATE498685T1 (de) Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
ATE397676T1 (de) Identifikation und verwendung von mirnas zur differenzierung myelogener leukämiezellen
DK2019692T3 (da) Forbindelser og fremgangsmåder til modulation af ekspression af gccr
ATE556711T1 (de) Verfahren zur verbesserung der hautqualität
EA200600591A1 (ru) МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
DE602006018354D1 (de) Verfahren zur behandlung von abnormalem zellwachstum
ATE554725T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
ATE530142T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
DE602005021336D1 (de) Verfahren zur identifizierung von proteinen mit stärkephosphorylierender enzymatischer aktivität
WO2005020921A3 (en) C-kit modulators and methods of use
DE602005009318D1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
ATE469908T1 (de) Verfahren zur herstellung von pimecrolimus
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE533838T1 (de) Verfahren zur verbesserten einführung von dna in bakterienzellen
ATE527378T1 (de) Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression
EP1679964A4 (de) Zusammensetzungen mit bzw. verfahren zur verwendung von sirna-amphipathischen verbindungen und polykationen
ATE482966T1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
ATE480615T1 (de) Verfahren zur proliferation von stammzellen
EA200970407A1 (ru) Ингибиторы киназ mapk/erk

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties